Press Releases Year None202020192018201720162015201420132012 December 28, 2020 Lineage Cell Therapeutics Provides End of Year Shareholder Letter December 9, 2020 Lineage Cell Therapeutics to Present at the 13th Annual LD Micro Main Event Conference on December 14, 2020 December 8, 2020 Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury November 16, 2020 Lineage Cell Therapeutics Presents New OpRegen® Data for Dry AMD With GA at 2020 American Academy of Ophthalmology Annual Meeting November 13, 2020 Lineage Cell Therapeutics Proudly Supports Patients’ Access to Innovative Cell Therapy Treatments and Research Through Passage of Proposition 14 November 11, 2020 Lineage Cell Therapeutics Completes Patient Enrollment in Phase 1/2a Clinical Study of OpRegen® Cell Therapy for the Treatment of Dry Age-related Macular Degeneration November 4, 2020 Lineage Cell Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update November 2, 2020 Lineage Cell Therapeutics to Host Expert Call Following OpRegen® Data Update at 2020 American Academy of Ophthalmology Meeting October 28, 2020 Lineage Cell Therapeutics to Report Third Quarter 2020 Financial Results and Provide Business Update on November 4, 2020 October 15, 2020 OpRegen Data Update to Be Featured in Presentation by Christopher D. Riemann, MD at 2020 American Academy of Ophthalmology Meeting October 13, 2020 Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer September 17, 2020 Lineage Cell Therapeutics to Present at FORCE Wealth Virtual Fireside Chat on September 23, 2020 September 10, 2020 Lineage Cell Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and at Cantor Virtual Global Healthcare Conference on September 17, 2020 September 9, 2020 Lineage Cell Therapeutics and AgeX Therapeutics Announce Expansion of Agreement Related to ESI Clinical-Grade Pluripotent Stem Cell Lines for Therapeutic Purposes September 8, 2020 Lineage Cell Therapeutics Awarded Grant From Israel Innovation Authority for Development of a Bio-Retinal Patch for Treatment of Retinal Diseases in Partnership With Precise Bio August 31, 2020 Lineage Cell Therapeutics Receives $24.6 Million Payment From Juvenescence Ltd. August 25, 2020 Lineage Cell Therapeutics to Present at LD Micro 500 Investor Conference and Solebury Trout Zoomside Chat on September 1, 2020 August 6, 2020 Lineage Cell Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on All Clinical Programs July 30, 2020 Lineage Cell Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020 July 6, 2020 Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant From Israel Innovation Authority June 25, 2020 Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for Spinal Cord Injury June 24, 2020 Lineage Cell Therapeutics to Present OpRegen® Data at International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting June 18, 2020 Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen® for the Treatment of Dry AMD With Geographic Atrophy June 17, 2020 Lineage Cell Therapeutics to Present Tomorrow at 2020 Raymond James Human Health Innovation Conference June 11, 2020 Lineage Cell Therapeutics to Present at 2020 Raymond James Human Health Innovation Conference on June 18, 2020 June 8, 2020 Lineage Cell Therapeutics to Host Therapeutic Expert Call Today to Discuss the First Known Reported Finding of Retinal Tissue Regeneration with OpRegen® in Dry AMD with Geographic Atrophy June 1, 2020 Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy May 19, 2020 Lineage Cell Therapeutics to Participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020 May 18, 2020 Lineage Cell Therapeutics to Present at 2020 Solebury Trout Virtual Investor Conference on May 26, 2020 May 7, 2020 Lineage Cell Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update May 7, 2020 Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program May 6, 2020 Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy May 5, 2020 Lineage Cell Therapeutics to Apply Allogeneic Dendritic Cell Therapy Program to COVID-19 Vaccine Development April 29, 2020 Lineage Cell Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020 April 24, 2020 Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation April 16, 2020 Lineage Cell Therapeutics CEO Letter March 12, 2020 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update March 5, 2020 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update on March 12, 2020 February 20, 2020 Lineage Cell Therapeutics to Present at Biocom’s 10th Annual Global Life Sciences Partnering Conference February 18, 2020 Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020) February 10, 2020 Lineage Cell Therapeutics to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference February 6, 2020 Lineage Provides Positive Update on Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration January 2, 2020 Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation
December 9, 2020 Lineage Cell Therapeutics to Present at the 13th Annual LD Micro Main Event Conference on December 14, 2020
December 8, 2020 Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury
November 16, 2020 Lineage Cell Therapeutics Presents New OpRegen® Data for Dry AMD With GA at 2020 American Academy of Ophthalmology Annual Meeting
November 13, 2020 Lineage Cell Therapeutics Proudly Supports Patients’ Access to Innovative Cell Therapy Treatments and Research Through Passage of Proposition 14
November 11, 2020 Lineage Cell Therapeutics Completes Patient Enrollment in Phase 1/2a Clinical Study of OpRegen® Cell Therapy for the Treatment of Dry Age-related Macular Degeneration
November 4, 2020 Lineage Cell Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 2, 2020 Lineage Cell Therapeutics to Host Expert Call Following OpRegen® Data Update at 2020 American Academy of Ophthalmology Meeting
October 28, 2020 Lineage Cell Therapeutics to Report Third Quarter 2020 Financial Results and Provide Business Update on November 4, 2020
October 15, 2020 OpRegen Data Update to Be Featured in Presentation by Christopher D. Riemann, MD at 2020 American Academy of Ophthalmology Meeting
October 13, 2020 Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer
September 17, 2020 Lineage Cell Therapeutics to Present at FORCE Wealth Virtual Fireside Chat on September 23, 2020
September 10, 2020 Lineage Cell Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and at Cantor Virtual Global Healthcare Conference on September 17, 2020
September 9, 2020 Lineage Cell Therapeutics and AgeX Therapeutics Announce Expansion of Agreement Related to ESI Clinical-Grade Pluripotent Stem Cell Lines for Therapeutic Purposes
September 8, 2020 Lineage Cell Therapeutics Awarded Grant From Israel Innovation Authority for Development of a Bio-Retinal Patch for Treatment of Retinal Diseases in Partnership With Precise Bio
August 25, 2020 Lineage Cell Therapeutics to Present at LD Micro 500 Investor Conference and Solebury Trout Zoomside Chat on September 1, 2020
August 6, 2020 Lineage Cell Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on All Clinical Programs
July 30, 2020 Lineage Cell Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020
July 6, 2020 Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant From Israel Innovation Authority
June 25, 2020 Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for Spinal Cord Injury
June 24, 2020 Lineage Cell Therapeutics to Present OpRegen® Data at International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
June 18, 2020 Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen® for the Treatment of Dry AMD With Geographic Atrophy
June 17, 2020 Lineage Cell Therapeutics to Present Tomorrow at 2020 Raymond James Human Health Innovation Conference
June 11, 2020 Lineage Cell Therapeutics to Present at 2020 Raymond James Human Health Innovation Conference on June 18, 2020
June 8, 2020 Lineage Cell Therapeutics to Host Therapeutic Expert Call Today to Discuss the First Known Reported Finding of Retinal Tissue Regeneration with OpRegen® in Dry AMD with Geographic Atrophy
June 1, 2020 Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy
May 19, 2020 Lineage Cell Therapeutics to Participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020
May 18, 2020 Lineage Cell Therapeutics to Present at 2020 Solebury Trout Virtual Investor Conference on May 26, 2020
May 7, 2020 Lineage Cell Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 7, 2020 Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program
May 6, 2020 Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy
May 5, 2020 Lineage Cell Therapeutics to Apply Allogeneic Dendritic Cell Therapy Program to COVID-19 Vaccine Development
April 29, 2020 Lineage Cell Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020
March 12, 2020 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 5, 2020 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update on March 12, 2020
February 20, 2020 Lineage Cell Therapeutics to Present at Biocom’s 10th Annual Global Life Sciences Partnering Conference
February 18, 2020 Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020)
February 10, 2020 Lineage Cell Therapeutics to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference
February 6, 2020 Lineage Provides Positive Update on Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration